Article in Pediatric blood & cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 5 institutions in 1 country.
Adeline YangDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0003-1966-6542
Alison PattersonPauline Allen Gill Center for Cancer and Blood Disorders, Children's Medical Center, Dallas, Texas.
Tara PavlockDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.
Kenneth S ChenDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0003-2304-4631
Jeffrey GaganDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
Mark E HatleyDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
A Lindsay FrazierDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-4748-8552
James F AmatrudaDivision of Hematology-Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.
Theodore W LaetschDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-8497-3138
Dinesh RakhejaChildren's Medical Center, Dallas, Texas.
Children's Medical Center · USHarvard University · USSt. Jude Children's Research Hospital · USThe University of Texas Southwestern Medical Center · USUniversity of Southern California · US
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
NORTH AND CENTRAL TEXAS CTSA FOR PEDIATRIC RESEARCHUL1RR024982 · NCRR · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2007 to 2011
$27.9M
Defining the non-myogenic origins of pediatric rhabdomyosarcomaR01CA216344 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HATLEY, MARK EDWARD · 2017 to 2021
$2.0M
Mediators Of Arrested Differentiation In Pediatric RhabdomyosarcomaR01CA251436 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HATLEY, MARK EDWARD · 2021 to 2025
Though outcomes for patients with recurrent/refractory malignant germ cell tumors (mGCTs) are poor, therapies targeting mTOR and EGFR inhibition have shown promise in vitro. We hypothesized that the combination of sirolimus and erlotinib will show activity in patients with recurrent/refractory mGCTs. Patients were enrolled in a prospective phase II clinical trial; central review of existing pathology specimens was performed. Of the five patients evaluated, two had their diagnoses revised to pancreatic acinar cell carcinoma and alpha-fetoprotein (AFP)-secreting gastric adenocarcinoma, respectively. Although mGCTs are common AFP-secreting neoplasms, recurrence or refractoriness to standard regimens should prompt histologic reevaluation for other diagnoses.
Indexed as
Endodermal Sinus TumorNeoplasms, Germ Cell and Embryonalalpha-FetoproteinsClinical Trials, Phase II as TopicHumansNeoplasm Recurrence, LocalProspective Studiesalpha-Fetoproteinsalpha-fetoprotein-secreting gastric adenocarcinomamalignant germ cell tumorpancreatic acinar cell carcinomarefractoryrelapseyolk sac tumor
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Pitfalls in the diagnosis of yolk sac tumor: Lessons from a clinical trial. · full record | Socratic